FDA
-
-
-
-
-
-
-
Wolfe Research Starts CytomX Therapeutics (CTMX) at Outperform
-
-
-
-
-
-
-
Cardiff Oncology appoints interim CEO as executives step down
-
-
-
-
-
-
-
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
-
-
-
-
-
-
-
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)
-
-
-
-
-
-
-
CytomX Therapeutics Announces Third Quarter 2018 Financial Results
-
-
-
-
-
-
-
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

